房颤拜瑞妥进医保了吗？是不是医保药？拜瑞妥在医保范围吗？

Is Xarelto for atrial fibrillation covered by medical insurance? Is it a medical insurance drug? Is Xarelto covered by health insurance? Xarelto (rivaroxaban) is currently included in medical insurance, and patients can be reimbursed by medical insurance after purchasing the drug. Xarelto (rivaroxaban), developed by Bayer in Germany, (rivaroxaban) is a highly selective oral drug that directly inhibits factor xa. By inhibiting factor xa, it can interrupt the endogenous and exogenous pathways of the coagulation waterfall, inhibit the generation of thrombin and thrombosis, and has a safe, effective, simple and intuitive anticoagulant effect.

Xarelto (Rivaroxaban) is mainly indicated for the treatment of venous thrombosis in adults. It is also used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). Rivaroxaban is used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack).

A researcher included 80 patients with venous thromboembolism in the study. The results showed that Xarelto (rivaroxaban) has an obvious effect in treating patients with venous thromboembolism. It will not inhibit the patient's coagulation function, nor will it have a major impact on the patient's cardiac function. It is highly safe and worthy of recommendation.

Treat DVT (venous thrombosis) and reduce the risk of acute DVT recurrence and PE: The recommended dose of Xarelto (rivaroxaban) for the initial treatment of acute DVT is 15 mg twice a day for the first three weeks, and then the dose for maintenance treatment and to reduce the risk of DVT recurrence and PE is 20 mg once a day.

Rivaroxaban is used in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism: the recommended dose of Rivaroxaban is 20 mg once a day, which is also the maximum recommended dose. For patients with low weight and advanced age (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: